Market Overview

Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on June 6)

  • AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
  • Baxter International Inc (NYSE: BAX)
  • Beigene Ltd (ADR) (NASDAQ: BGNE)
  • CareDx Inc (NASDAQ: CDNA)
  • CAS Medical Systems Inc (NASDAQ: CASM)
  • CONMED Corporation (NASDAQ: CNMD)
  • Champions Oncology Inc (NASDAQ: CSBR)
  • Cytosorbents Corp (NASDAQ: CTSO)
  • Eloxx Pharmaceuticals Inc (NASDAQ: ELOX)
  • Evolus Inc (NASDAQ: EOLS)
  • EXACT Sciences Corporation (NASDAQ: EXAS)
  • Genomic Health, Inc. (NASDAQ: GHDX)
  • Haemonetics Corporation (NYSE: HAE)
  • Insulet Corporation (NASDAQ: PODD)
  • Jazz Pharmaceuticals PLC (NASDAQ: JAZZ
  • Krystal Biotech Inc (NASDAQ: KRYS)
  • Laboratory Corp. of America Holdings (NYSE: LH)
  • Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)
  • Medpace Holdings Inc (NASDAQ: MEDP)
  • MEI Pharma Inc (NASDAQ: MEIP)
  • ResMed Inc. (NYSE: RMD)
  • Oncolytics Biotech, Inc. (USA) (NASDAQ: ONCY)
  • Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)
  • Regenxbio Inc (NASDAQ: RGNX)
  • Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)
  • TherapeuticsMD Inc (NASDAQ: TXMD)
  • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)
  • Verastem Inc (NASDAQ: VSTM)

Down In The Dumps

(Stocks hitting 52-week lows on June 6)

  • Achieve Life Sciences Inc (NASDAQ: ACHV)
  • Scpharmaceuticals Inc (NASDAQ: SCPH)
  • TrovaGene (NASDAQ: TROV)

Related Link: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Stocks In Focus

Johnson & Johnson to Sell Sterilization Business to Fortive

Johnson & Johnson (NYSE: JNJ) announced a deal to sell its Advanced Sterilization Products, or ASP, business to Fortive Corp (NYSE: FTV) for $2.8 billion, with $2.7 billion in cash proceeds and the remaining $0.1 billion in retained net receivables. The ASP business fetched Johnson & Johnson $775 million in net revenues in 2017.

Fortive rallied 5.46 percent to $79.05 in after-hours trading.

Protesostasis Cystic Fibrosis Drug Trial Shows Issues With Safety

Proteostasis Therapeutics Inc (NASDAQ: PTI) announced data from the Phase 1, 14-day dosing study of PTI-801 in cystic fibrosis patients on background Orkambi (lumacaftor/ivacaftor) therapy, which showed improvement in sweat chloride and body mass index, the study's exploratory endpoints.

"At higher doses, PTI-801 demonstrated a statistically significant improvement in SC and BMI in the 14-day treatment period," the company said.

The improvement in ppFEV – reflective of lung function, though observed in all cohorts, was not statistically significant, the company added.

The stock plunged 15.92 percent to $4.12 in after-hours trading.

Common Stock Offerings

Viking Therapeutics Inc (NASDAQ: VKTXannounced offering of common shares for development of its VK5211, VK2809 and VK0214 programs.

Mirati Therapeutics Inc (NASDAQ: MRTX) announced intention for offering common share.

Pricing Of Common Stock Offerings

Zymeworks Inc (NYSE: ZYME) priced offering of 5.4 million shares at $15.75/share for gross proceeds of $300 million.

Madrigal Pharma priced offering of 1.347 million shares at $305/share for gross proceeds of $85.1 million.

Deciphera Pharmaceuticals Inc (NASDAQ: DCPHpriced offering of 4.3 million share at $40/share for gross proceeds of $172 million.

ImmunoGen, Inc. (NASDAQ: IMGNpriced its upsized offering of 13.7 million shares.

On The Radar

The following company reports earnings on Thursday:

  • Advaxis, Inc. (NASDAQ: ADXS)

FDA Tidbits

The FDA filed a compliant against Innovative BioDefense, which sells Zylast topical antiseptics, a hand sanitizer, by falsely claiming it offers protection against pathogens such as norovirus, rotavirus, flu virus, methicillin-resistant Staphylococcus Aureus and ebola.

Posted-In: Biotech Earnings News Trading Ideas Best of Benzinga


Related Articles (ADXS + ACHV)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

27 Stocks Moving In Thursday's Pre-Market Session

Earnings Outlook For Iteris